ヒトアルファ1-プロテアーゼ阻害剤の世界市場インサイト・予測(~2025年)

QYResearchが発行した調査報告書(QYR20FB08435)
◆英語タイトル:Global Human Alpha1-Proteinase Inhibitor Market Insights, Forecast to 2025
◆商品コード:QYR20FB08435
◆発行会社(リサーチ会社):QYResearch
◆発行日:2019年12月11日(※2024年版があります。お問い合わせください。)
◆ページ数:112
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、世界のヒトアルファ1-プロテアーゼ阻害剤市場について調査・分析し、以下の構成でお届け致します。ヒトアルファ1-プロテアーゼ阻害剤の種類別には、0.5g、1gに、用途別には、病院、薬局に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。

・調査販売
・エグゼクティブ・サマリー
・企業別ヒトアルファ1-プロテアーゼ阻害剤売上データ
・地域別ヒトアルファ1-プロテアーゼ阻害剤市場規模:北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他
・種類別ヒトアルファ1-プロテアーゼ阻害剤市場規模:0.5g、1g
・用途別ヒトアルファ1-プロテアーゼ阻害剤市場規模:病院、薬局
・主要メーカーの企業情報:Baxter、Kamada、Talecris Biotherapeutics、Aventis Behring
・ヒトアルファ1-プロテアーゼ阻害剤の市場規模予測
・バリューチェーン及び販売チャネル分析
・市場機会・課題・リスク・影響因子分析
...
【レポートの概要】

The global Human Alpha1-Proteinase Inhibitor market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Human Alpha1-Proteinase Inhibitor market based on company, product type, end user and key regions.
This report studies the global market size of Human Alpha1-Proteinase Inhibitor in key regions like North America, Europe, China and Japan, focuses on the consumption of Human Alpha1-Proteinase Inhibitor in these regions.
This research report categorizes the global Human Alpha1-Proteinase Inhibitor market by top players/brands, region, type and end user. This report also studies the global Human Alpha1-Proteinase Inhibitor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Baxter
Kamada
Talecris Biotherapeutics
Aventis Behring

Human Alpha1-Proteinase Inhibitor market size by Type
0.5g
1g

Human Alpha1-Proteinase Inhibitor market size by Applications
Hospital
Pharmacy

Market size by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Central & South America
Brazil
Middle East & Africa
Turkey
GCC Countries
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Human Alpha1-Proteinase Inhibitor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Human Alpha1-Proteinase Inhibitor market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Human Alpha1-Proteinase Inhibitor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Human Alpha1-Proteinase Inhibitor submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Human Alpha1-Proteinase Inhibitor are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Human Alpha1-Proteinase Inhibitor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Study Coverage
1.1 Human Alpha1-Proteinase Inhibitor Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Human Alpha1-Proteinase Inhibitor Market Size Growth Rate by Type
1.4.2 0.5g
1.4.3 1g
1.5 Market by Application
1.5.1 Global Human Alpha1-Proteinase Inhibitor Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Human Alpha1-Proteinase Inhibitor Market Size
2.1.1 Global Human Alpha1-Proteinase Inhibitor Revenue 2014-2025
2.1.2 Global Human Alpha1-Proteinase Inhibitor Sales 2014-2025
2.2 Human Alpha1-Proteinase Inhibitor Growth Rate by Regions
2.2.1 Global Human Alpha1-Proteinase Inhibitor Sales by Regions
2.2.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Human Alpha1-Proteinase Inhibitor Sales by Manufacturers
3.1.1 Human Alpha1-Proteinase Inhibitor Sales by Manufacturers
3.1.2 Human Alpha1-Proteinase Inhibitor Sales Market Share by Manufacturers
3.2 Human Alpha1-Proteinase Inhibitor Revenue by Manufacturers
3.2.1 Human Alpha1-Proteinase Inhibitor Revenue by Manufacturers (2014-2019)
3.2.2 Human Alpha1-Proteinase Inhibitor Revenue Share by Manufacturers (2014-2019)
3.3 Human Alpha1-Proteinase Inhibitor Price by Manufacturers
3.4 Human Alpha1-Proteinase Inhibitor Manufacturing Base Distribution, Product Types
3.4.1 Human Alpha1-Proteinase Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Human Alpha1-Proteinase Inhibitor Product Type
3.4.3 Date of International Manufacturers Enter into Human Alpha1-Proteinase Inhibitor Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Human Alpha1-Proteinase Inhibitor Sales by Type
4.2 Global Human Alpha1-Proteinase Inhibitor Revenue by Type
4.3 Human Alpha1-Proteinase Inhibitor Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Human Alpha1-Proteinase Inhibitor Breakdown Data by Application

6 North America
6.1 North America Human Alpha1-Proteinase Inhibitor by Country
6.1.1 North America Human Alpha1-Proteinase Inhibitor Sales by Country
6.1.2 North America Human Alpha1-Proteinase Inhibitor Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Human Alpha1-Proteinase Inhibitor by Type
6.3 North America Human Alpha1-Proteinase Inhibitor by Application

7 Europe
7.1 Europe Human Alpha1-Proteinase Inhibitor by Country
7.1.1 Europe Human Alpha1-Proteinase Inhibitor Sales by Country
7.1.2 Europe Human Alpha1-Proteinase Inhibitor Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Human Alpha1-Proteinase Inhibitor by Type
7.3 Europe Human Alpha1-Proteinase Inhibitor by Application

8 Asia Pacific
8.1 Asia Pacific Human Alpha1-Proteinase Inhibitor by Region
8.1.1 Asia Pacific Human Alpha1-Proteinase Inhibitor Sales by Region
8.1.2 Asia Pacific Human Alpha1-Proteinase Inhibitor Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Thailand
8.1.10 Malaysia
8.1.11 Philippines
8.1.12 Vietnam
8.2 Asia Pacific Human Alpha1-Proteinase Inhibitor by Type
8.3 Asia Pacific Human Alpha1-Proteinase Inhibitor by Application

9 Central & South America
9.1 Central & South America Human Alpha1-Proteinase Inhibitor by Country
9.1.1 Central & South America Human Alpha1-Proteinase Inhibitor Sales by Country
9.1.2 Central & South America Human Alpha1-Proteinase Inhibitor Revenue by Country
9.1.3 Brazil
9.2 Central & South America Human Alpha1-Proteinase Inhibitor by Type
9.3 Central & South America Human Alpha1-Proteinase Inhibitor by Application

10 Middle East and Africa
10.1 Middle East and Africa Human Alpha1-Proteinase Inhibitor by Country
10.1.1 Middle East and Africa Human Alpha1-Proteinase Inhibitor Sales by Country
10.1.2 Middle East and Africa Human Alpha1-Proteinase Inhibitor Revenue by Country
10.1.3 Turkey
10.1.4 GCC Countries
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Human Alpha1-Proteinase Inhibitor by Type
10.3 Middle East and Africa Human Alpha1-Proteinase Inhibitor by Application

11 Company Profiles
11.1 Baxter
11.1.1 Baxter Company Details
11.1.2 Company Business Overview
11.1.3 Baxter Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Baxter Human Alpha1-Proteinase Inhibitor Products Offered
11.1.5 Baxter Recent Development
11.2 Kamada
11.2.1 Kamada Company Details
11.2.2 Company Business Overview
11.2.3 Kamada Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Kamada Human Alpha1-Proteinase Inhibitor Products Offered
11.2.5 Kamada Recent Development
11.3 Talecris Biotherapeutics
11.3.1 Talecris Biotherapeutics Company Details
11.3.2 Company Business Overview
11.3.3 Talecris Biotherapeutics Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Talecris Biotherapeutics Human Alpha1-Proteinase Inhibitor Products Offered
11.3.5 Talecris Biotherapeutics Recent Development
11.4 Aventis Behring
11.4.1 Aventis Behring Company Details
11.4.2 Company Business Overview
11.4.3 Aventis Behring Human Alpha1-Proteinase Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Aventis Behring Human Alpha1-Proteinase Inhibitor Products Offered
11.4.5 Aventis Behring Recent Development

12 Future Forecast
12.1 Human Alpha1-Proteinase Inhibitor Market Forecast by Regions
12.1.1 Global Human Alpha1-Proteinase Inhibitor Sales Forecast by Regions 2019-2025
12.1.2 Global Human Alpha1-Proteinase Inhibitor Revenue Forecast by Regions 2019-2025
12.2 Human Alpha1-Proteinase Inhibitor Market Forecast by Type
12.2.1 Global Human Alpha1-Proteinase Inhibitor Sales Forecast by Type 2019-2025
12.2.2 Global Human Alpha1-Proteinase Inhibitor Revenue Forecast by Type 2019-2025
12.3 Human Alpha1-Proteinase Inhibitor Market Forecast by Application
12.4 North America Human Alpha1-Proteinase Inhibitor Forecast
12.5 Europe Human Alpha1-Proteinase Inhibitor Forecast
12.6 Asia Pacific Human Alpha1-Proteinase Inhibitor Forecast
12.7 Central & South America Human Alpha1-Proteinase Inhibitor Forecast
12.8 Middle East and Africa Human Alpha1-Proteinase Inhibitor Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Human Alpha1-Proteinase Inhibitor Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

Baxter、Kamada、Talecris Biotherapeutics、Aventis Behring

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ヒトアルファ1-プロテアーゼ阻害剤の世界市場インサイト・予測(~2025年)(Global Human Alpha1-Proteinase Inhibitor Market Insights, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。